Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC9204-0530 in overweight or obese subjects
NCT02835235Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jul 2016
- Primary completion
- Jul 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing NNC9204-0530 with Placebo (2 arms). Primary endpoint: Number of treatment emergent adverse events at 112 days. Started Jul 2016; status: completed.
02
Drugs
NNC9204-0530
03
Conditions
obesity
Beyond the preview
Go deeper on NCT02835235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02835235.